AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys.
AT-7687,一種新型 GIPR 肽拮抗劑,與 GLP-1 激動劑聯合使用,可促進猕猴的體重減輕和代謝改善。
Mol Metab 2024-08-11
Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates.
GLP-1/GDF15雙重激動劑在老鼠和非人類靈長類動物中減輕體重和代謝紊亂。
Cell Metab 2023-03-22
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity.
「雙胰島素依賴性胰島素促分泌肽/葡萄糖樣肽-1 受體激動劑對肥胖者體重減輕的影響」。
Front Endocrinol (Lausanne) 2023-03-14
Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss.
針對葡萄糖依賴性胰島素增生多肽受體 (GIPR) 的新型治療藥物設計,以協助減重。
Expert Opin Drug Discov 2023-05-30
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
一種與 GLP-1 類似物結合的 GIPR 拮抗劑,在臨床前和第一階段試驗中促進減重並改善代謝參數。
Nat Metab 2024-02-29
An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.
一種GLP-1R/GIPR共激動劑肽的不平衡形式,具有特定位置的N端PEG化,以最大化代謝益處。
iScience 2024-03-22
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus.
DR10627,一種新型雙胰高血糖素樣肽-1和胃抑制性多肽受體激動劑,用於肥胖症和第2型糖尿病的治療。
Diabetes Metab Syndr Obes 2024-04-25
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity.
肥胖症治療的研究性和新興胃抑制性胰高血糖素多肽(GIP)受體相關療法。
Expert Opin Investig Drugs 2024-07-10
The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.
新型嵌合多激動肽 (GEP44) 以胰高血糖素樣肽-1 受體依賴的方式減少雄性和雌性飲食誘導肥胖小鼠的能量攝取和體重。
Front Endocrinol (Lausanne) 2024-08-06